Development status: Approved in Japan, off-patent, available in some countries

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Binds to type II topoisomerases, gyrase and topoisomerase IV and thus, inhibits DNA cleavage and ligation reactions. It kills bacterial cells by increasing the concentration of enzyme–DNA cleavage complexes, thereby inhibiting cell replication.

Additional information: Synthetic quinoline derivative, prodrug of ulifloxacin. Very similar to ciprofloxacin.